ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

FHS
May 21, 2024
5:03 am

ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio.

Edoxaban monotherapy superior to dual therapy in patients with high-risk AF and stable CAD

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk

September 2, 2024

Is Alzheimer’s Transmissible Through Bone Marrow Cells?

A mouse experiment suggested familial Alzheimer’s disease may be transmitted through bone marrow stem cells, but the implications of the findings were limited. The research

March 30, 2024

What does it mean to be ‘in recovery’? We need a better federal definition

“When I use a word,” one of 19th century British author and mathematician Lewis Carroll’s characters once said, “it means just what I choose it

July 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.